Source comparison
CJC-1295 vs IGF-1 LR3: Side-by-Side Mechanism Comparison
| Peptide | Mechanism of Action | Primary Target | Half-Life | Feedback Regulation | Serum IGF-1 Source | Tissue Selectivity ||—|—|—|—|—|—|| CJC-1295 | GHRH receptor agonist. Binds anterior pituitary somatotrophs to amplify endogenous GH pulsatility | Pituitar
This comparison does not assign a generated winner or score.
- | Peptide | Mechanism of Action | Primary Target | Half-Life | Feedback Regulation | Serum IGF-1 Source | Tissue Selectivity ||—|—|—|—|—|—|| CJC-1295 | GHRH receptor agonist. Binds anterior pituitary somatotrophs to amplify endogenous GH pulsatility | Pituitary GHRH receptors | 6–8 days (albumin-bound) | Yes. Subject to somatostatin, circadian rhythm, nutrient signaling | Hepatic production via GH-stimulated JAK2/STAT5 | Non-selective. Systemic GH elevation affects all GH-responsive tissue || IGF-1 LR3 | Direct IGF-1 receptor agonist. Bypasses GH axis entirely and activates PI3K/Akt, mTOR pathways at tissue level | IGF-1 receptors on muscle, adipose, connective tissue | 20–30 hours | No. Exogenous peptide not subject to physiological feedback loops | Exogenous (injected). Does not require liver conversion | Potentially selective based on injection site, though systemic distribution occurs |
- The 'Bottom Line' column here: CJC-1295 leverages your existing growth axis and stays within its regulatory boundaries. IGF-1 LR3 doesn't. If your research question involves observing natural GH pulsatility under amplified conditions, CJC-1295 is the mechanistically appropriate choice. If you need sustained, high-level IGF-1 receptor activation independent of pituitary function, IGF-1 LR3 delivers that. But you're trading physiological regulation for pharmacological override.